Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacist support may boost rheumatoid arthritis treatment — a trial puts it to the test

NCT ID NCT07726355

Disease control Sponsor: Deraya University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether adding a clinical pharmacist to standard drug therapy helps people with early rheumatoid arthritis achieve better disease control. Participants receive pharmacist-led education, counseling, and medication management alongside their usual DMARD treatment. The study aims to see if this combined approach improves disease activity, medication adherence, and quality of life compared to standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clinical pharmacist-led education and counseling alongside standard DMARD therapy
What this could lead to
If it works, this could point toward a more effective care model for early rheumatoid arthritis that combines medication with pharmacist support to improve disease control and quality of life.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. The benefit of pharmacist intervention over standard care alone remains unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

70 people

The number who actually took part.

Started

Apr 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18-65 years. * Diagnosis of early RA according to the 2010 ACR/EULAR classification criteria. * Disease lasts less than 2 years. * Presence of at least one tender and one swollen joint. * Ability to provide informed consent. Exclusion Criteria: * Use of oral glucocorticoids \>10 mg/day during the previous 3 weeks. * Current biological DMARD therapy. * AST or ALT \>3 times the upper limit of normal. * eGFR \<30 mL/min/1.73 m². * Active infection. * Malignancy. * Pregnancy or lactation. * Other autoimmune or musculoskeletal disorders. * Inability to participate in follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early rheumatoid arthritis

Contacts and locations

Locations

  • Assiut university

    Minya, Egypt